Needham Maintains Buy on Xenon Pharmaceuticals, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Xenon Pharmaceuticals (NASDAQ:XENE) and raises the price target from $50 to $62.
March 01, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Xenon Pharmaceuticals and raises the price target from $50 to $62.
The increase in the price target by a reputable analyst indicates a strong positive outlook on the stock, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100